Effect of CTAP101 Capsules on Serum Calcium, Plasma Intact Parathyroid Hormone and Vitamin D Metabolites in Patients With Advanced Breast or Prostate Carcinomas With Metastases to Bone and Receiving Ongoing Therapy With Denosumab or Zoledronic Acid
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Calcifediol (Primary)
- Indications Bone cancer; Breast cancer; Hyperparathyroidism; Prostate cancer
- Focus Adverse reactions; Pharmacodynamics
- Sponsors OPKO Health
- 20 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 11 Apr 2017 Planned End Date changed from 1 Feb 2017 to 1 Dec 2018.